Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel
LON:TCF

Theracryf Interim Earnings Report

GBX 0.18 -0.01 (-3.16%)
As of 11:35 AM Eastern
ProfileEarnings History

Theracryf EPS Results

Actual EPS
-GBX 29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Theracryf Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Theracryf Announcement Details

Quarter
Interim
Date
11/28/2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Theracryf Earnings Headlines

TheraCryf appoints new board member, issues options
May 2, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/theracryf-appoints-new-board-member-issues-options-93CH-4058518
Theracryf Plc (TCF.L)
January 18, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/TCF.L/hiring-trends/
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
August 26 at 1:00 AM  |  Porter & Company (Ad)
Theracryf PLC Share Chat (TCF)
January 13, 2025  |  lse.co.ukhttps://www.lse.co.uk/ShareChat.html?ShareTicker=TCF&thread=D6EDFB9D-E83F-43D6-8E6C-4DBC80FD8FDF
See More Theracryf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theracryf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theracryf and other key companies, straight to your email.

About Theracryf

Theracryf (LON:TCF) is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

View Theracryf Profile
Earnings Tools